Ganitumab

Drug Profile

Ganitumab

Alternative Names: AMG-479

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Millennium; NantWorks; National Cancer Institute (USA); Novartis; Takeda; Takeda Oncology; UCLAs Jonsson Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ewing's sarcoma
  • Phase II Solid tumours
  • Phase Unknown Rhabdomyosarcoma
  • No development reported Breast cancer; Colorectal cancer; Sarcoma; Small cell lung cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 01 Jun 2017 NantCell completes a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease) in USA, Belgium, Canada and Spain (IV) (NCT01708161)
  • 10 Apr 2017 Ganitumab receives Orphan Drug status for Ewing's Sarcoma in USA
  • 10 Feb 2017 National Cancer Institute plans a phase I/II trial for Rhabdomyosarcoma in USA (NCT03041701)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top